Matej Msc Roder

Matej Msc Roder

Auto-generated profile, based on publicly available information

Matej Msc Roder

Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Transplantation Direct
Verified
Journal Article
Open access
OVOndrej Viklicky
Ondrej Viklicky
PHPetra Hruba
Petra Hruba
MNMarek Novotny
Marek Novotny
MKMartin Kment
Martin Kment
MRMatej Roder
Matej Roder
GBGeorg A. Böhmig
Georg A. Böhmig

17 May 2024 in Transplantation Direct
Verified
Journal Article
Open access
VPVojtech Petr
Vojtech Petr
IZIvan Zahradka
Ivan Zahradka
IMIstvan Modos
Istvan Modos
MRMatej Msc Roder
Matej Msc Roder
MFMartina Msc Fialova
Martina Msc Fialova
OVOndrej Viklicky
Ondrej Viklicky
Background. Booster doses of SARS-CoV-2 mRNA vaccines are commonly used in kidney transplant recipients (KTRs). However, there is uncertainty regarding the waning of vaccination responses and immunological safety in KTRs. Methods. A total of 123 KTRs were included in the final analysis of this prospective observational cohort study. The aim was to evaluate the immunogenicity and immunological safety. SARS-CoV-2 antispike IgG antibodies and anti-HLA antibodies were measured at baseline and then at months 3, 6, and 12 after vaccination with the first booster dose (ie, the third vaccine dose). Antibodies against S1 and S2 subunits of SARS-CoV-2 were evaluated using an immunochemiluminescent assay (cutoff 9.5 AU/mL, sensitivity 91.2%, and specificity 90.2%). Anti-HLA antibodies were analyzed using single-antigen bead technology. Results. Seroconversion was reached in 65% of KTRs previously nonresponding to 2-dose mRNA vaccination; the overall seroconversion rate 3 mo after the first booster dose was 83%. Vaccination induced a durable humoral response, and the antibody levels were stable during the 12-mo study follow-up. Higher age (exponentiated beta coefficient [eβ] 0.97; 95% confidence interval [CI], 0.943-0.997) and a full dose of mycophenolate (eβ 0.296; 95% CI, 0.089-0.984) were negatively associated with SARS-CoV-2 IgG antibody levels, whereas better graft function (eβ1.021; 95% CI, 1.005-1.037) was associated positively. There were no systematic signs of anti-HLA antibody development after vaccination. However, during the follow-up, there was a nonsignificant signal of an increase in anti-HLA antibodies in those who developed COVID-19. Conclusions. Additional booster doses of SARS-CoV-2 mRNA vaccines induce durable antibody response even in a large subset of previous nonresponders and are not associated with the risk of allosensitization. Furthermore, a signal linking COVID-19 to the development of anti-HLA antibodies was observed, and this should be confirmed and further examined (NCT05483725).